Provention Bio to Develop Two Janssen GI Immunology Candidates

Johnson & Johnson entities Janssen Pharmaceutica and Janssen Sciences Ireland have outlicensed two gastrointestinal immunology candidates to a startup launched earlier this year, under agreements whose value was not disclosed.Provention Bio said it will launch clinical trials for the two candidates in the first half of 2018.One candidate is PRV-6527 (JNJ-40346527), an oral colony stimulating factor-1 receptor (CSF-1R) small molecule inhibitor, for which Provention expects to begin patient en